ciprofibrate has been researched along with Arteriosclerosis in 10 studies
Arteriosclerosis: Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ciprofibrate is an effective hypolipidemic agent, also lowering the level of fibrinogen." | 5.30 | [The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia]. ( Cibulova, L; Fedelesova, V; Gajdos, M; Huttova, D; Krivosikova, Z; Mongiellova, V; Polak, F, 1999) |
| "Ciprofibrate did not inhibit thromboxane B 2 synthesis in platelets." | 2.70 | Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects. ( Cibulová, L; Dzúrik, R; Gajdos, M; Huttová, D; Krivosíková, Z; Mongiellová, V; Spustová, V, 2001) |
| "Ciprofibrate has a potent hypolipidemic effect, especially a decrease in triglycerides, VLDL and fibrinogen, and an increase in HDL-cholesterol, but does not influence glycemic control nor insulin action." | 2.69 | Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects. ( Ascaso, JF; Carmena, R; Hernández-Mijares, A; Lluch, I; Martínez-Triguero, ML; Vizcarra, E, 2000) |
| "Dyslipidaemia in patients with type 2 diabetes commonly consists of elevated triglyceride levels; normal or slightly elevated low-density lipoprotein (LDL)-cholesterol levels with a preponderance of small, dense LDL particles; and low high-density lipoprotein (HDL)-cholesterol levels with a preponderance of small, dense HDL." | 2.42 | LDL-cholesterol, HDL-cholesterol or triglycerides--which is the culprit? ( Taskinen, MR, 2003) |
| "Ciprofibrate is a hypolipidaemic compound that acts primarily by enhancing the oxidation of fatty acids in the liver and, consequently, decreasing the production of hepatic VLDL." | 1.32 | The peroxisome-proliferator-activated receptor alpha agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E. ( Borensztajn, J; Fu, T; Kashireddy, P, 2003) |
| "Ciprofibrate is an effective hypolipidemic agent, also lowering the level of fibrinogen." | 1.30 | [The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia]. ( Cibulova, L; Fedelesova, V; Gajdos, M; Huttova, D; Krivosikova, Z; Mongiellova, V; Polak, F, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 7 (70.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, T | 2 |
| Kashireddy, P | 1 |
| Borensztajn, J | 2 |
| Taskinen, MR | 1 |
| Guerin, M | 1 |
| Le Goff, W | 1 |
| Frisdal, E | 1 |
| Schneider, S | 1 |
| Milosavljevic, D | 1 |
| Bruckert, E | 1 |
| Chapman, MJ | 1 |
| Mukhopadhyay, D | 1 |
| Davidson, NO | 1 |
| Irizar, A | 1 |
| Ioannides, C | 1 |
| Schonfeld, G | 1 |
| Gajdos, M | 2 |
| Fedelesova, V | 1 |
| Mongiellova, V | 2 |
| Cibulova, L | 2 |
| Huttova, D | 2 |
| Polak, F | 1 |
| Krivosikova, Z | 2 |
| Hernández-Mijares, A | 1 |
| Lluch, I | 1 |
| Vizcarra, E | 1 |
| Martínez-Triguero, ML | 1 |
| Ascaso, JF | 1 |
| Carmena, R | 1 |
| Dobiásová, M | 1 |
| Frohlich, J | 1 |
| Spustová, V | 1 |
| Dzúrik, R | 1 |
2 reviews available for ciprofibrate and Arteriosclerosis
| Article | Year |
|---|---|
LDL-cholesterol, HDL-cholesterol or triglycerides--which is the culprit?
Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Controlled Clinical Trials as | 2003 |
The effects of fibrates on lipoprotein and hemostatic coronary risk factors.
Topics: Arteriosclerosis; Bezafibrate; Blood Coagulation; Clofibric Acid; Coronary Disease; Fenofibrate; Fib | 1994 |
3 trials available for ciprofibrate and Arteriosclerosis
| Article | Year |
|---|---|
Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.
Topics: Adult; Animals; Apolipoprotein A-I; Apolipoproteins B; Arteriosclerosis; Cholesterol; Cholesterol Es | 2003 |
Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects.
Topics: Adult; Aged; Apolipoproteins B; Area Under Curve; Arteriosclerosis; Blood Glucose; Carbohydrate Meta | 2000 |
Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects.
Topics: Aged; Arteriosclerosis; Aspirin; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Fi | 2001 |
5 other studies available for ciprofibrate and Arteriosclerosis